UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 27, 2018

ITUS CORPORATION
(Exact name of registrant as specified in its charter)

Delaware	**000-11254**	**11-2622630**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3150 Almaden Expressway, Suite 250 **San Jose, CA**	**95118**
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: **(408) 708-9808**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Attached as Exhibit 99.1 to this Current Report is the form of presentation that ITUS Corporation (the "Company") used in connection with its presentation to Company stockholders at the Company's Annual Meeting of Stockholders on September 27, 2018.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit No.	Description
99.1	Corporate Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 27, 2018

ITUS CORPORATION

By: /s/ Dr. Amit Kumar
Name: Dr. Amit Kumar
Title: President and Chief Executive Officer

ITUS Corporation

Presentation: Annual Shareholder Meeting

September 27, 2018

NASDAQ:ITUS

Amit Kumar, Ph.D.

(Soon to Be Anixa Biosciences, Inc.)

Forward-Looking Statements

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A – Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

Outline

- Background and Reflection on the Last Year
- Plans and Goals for remainder of 2018 and 2019
- Update on both programs
  - Update on CAR-T program
  - Update on Cchek™
- Q&A

Background

- Management Change in July 2017
- Team with Amit Kumar, Ph.D. as CEO for roughly 14 months
  - John Roop, SVP Engineering
  - Mike Catelani, COO, CFO
  - Tony Campisi, VP Engineering
  - George Dominguez, Ph.D., Senior Scientist
  - Alex Polo, Scientist
  - Chereen Abushaaban, Office Manager

Leverage-Able Business Model



Major Accomplishments

- Licensed CAR-T Technology from The Wistar Institute
- Established Cooperative R&D Agreement with Moffitt Cancer Center
- Accelerated Development Timeline for CAR-T Program
- Requested Meeting with the FDA, Over a Year Ahead of Schedule

- Presented Cchek Data at Multiple Scientific Conferences
- Completed Blinded Study of Cchek with Memorial Sloan Kettering and Serametrix on prostate cancer
- Identified Prostate and Breast Cancer as Initial Commercial focus for Cchek

Stock Performance since July 2017



- Prefer not to predict stock price
  - Our primary goal is shareholder value creation
  - We have chosen to create shareholder value by engaging in the war against cancer
- Value Creation in Biotech can be Dramatic but Volatile

Goals for Calendar Q4-2018 and 2019- CAR-T

- Pre-IND (Investigational New Drug) Meeting with FDA
  - Meeting Scheduled for October 16, 2018
  - Written Communication Shortly After
- File IND Application
- Begin First in Human Clinical Trial (as early as calendar Q1/Q2-2019 time frame)
- Begin Business Development activities

Goals for Calendar Q4-2018 and 2019-Cchek™

- File Pre-IDE (Investigational Device Exemption) with FDA
- Meet with FDA-OIVD- Calendar Q4-2018 or Q1-2019
- Determine Commercialization Strategy
- Continue Presenting Data at Scientific Conferences
- Publish Data in Peer-Reviewed Publication
- Establish a Corporate Partnership

ITUS Corporate Goals

- Change Name to Anixa BioSciences, Ticker to ANIX- Next Week
  - No action needed by shareholders
  - Financial websites will update ticker within a day or two
- Achieve analyst coverage
- Create more visibility with Institutional Investors

Stockholder Comments and Questions

- We always return stockholder calls
  - May take time as we are a small team and busy
  - Prefer calls rather than emails even though they take more time
  - Please be cognizant of our time
  - Sometime in the near future, we hope to begin quarterly conference calls
- Please understand constraints on our responses
  - Many questions we cannot answer, as we are a public company
  - Shareholders are always telling us what to do

Update on Both Programs

Two specific initiatives utilizing an understanding and control of the dynamic interaction between tumors and the immune system

- Liquid Biopsy-- Cchek™
- Early Cancer Diagnostic
  - Early Detection Leads to Cures
  - Non-Invasive (blood test)
  - Inexpensive
  - Rapid
- CAR-T- Chimeric Antigen Receptor T-cells
- Therapy for Ovarian Cancer
  - Licensed Technology
  - Ovarian Cancer has poor prognosis
  - Immunotherapy

Update- CAR-T

- Ahead of schedule
- October 16, 2018 FDA Meeting
- Minutes from FDA in 30-60 days
- Assuming no further animal studies are needed:
  - We expect to file our IND in Calendar Q4-2018 or early 2019
  - We expect FDA approval to move to clinical trials
- Begin Human Testing in Calendar Q1/Q2- 2019
  - Open Label Clinical Trial
  - Dose Escalating Trial
  - Focused on Safety with Window to Efficacy
  - Goal is 18-24 Ovarian Cancer Patients
  - Speed of Trial will be dependent on Patient Recruitment

Update- Cchek™

- Artificial Intelligence (AI) better than scientist or physician
- May work for all cancers
- To date, identified in 20 different types
  - Majority: Breast and Prostate
  - Other: Lung, Colon, Pancreatic, Melanoma, Ovarian, Liver, Bladder, Cervical, Endometrial, Uterine, Gastric, Head and Neck, Testicular, Thyroid, and others
- Complete Benign Conditions Studies
- FDA IDE Application in Process
- Commercialization Partnership discussions

Questions